Abstract
Diabetic cystopathy (DCP) is a prevalent etiology of bladder dysfunction in individuals with longstanding diabetes, frequently leading to bladder interstitial fibrosis. Research investigating the initial pathological alterations of DCP is notably scarce. To comprehend the development of fibrosis and find effective biomarkers for its diagnosis, we prepared streptozotocin-induced long-term diabetic SD rats exhibiting a type 1 diabetes phenotype and bladder fibrosis in histology detection. After observing myofibroblast differentiation from rats' primary bladder fibroblasts with immunofluorescence, we isolated fibroblasts derived exosomes and performed exosomal miRNA sequencing. The co-differentially expressed miRNAs (DEMis) (miR-16-5p and let-7e-5p) were screened through a joint analysis of diabetic rats and long-term patients' plasma data (GES97123) downloaded from the GEO database. Then two co-DEMis were validated by quantitative PCR on exosomes derived from diabetic rats' plasma. Following with a series of analysis, including target mRNAs and transcription factors (TFs) prediction, hubgenes identification, protein-protein interaction (PPI) network construction and gene enrichment analysis, a miRNA-mediated genetic regulatory network consisting of two miRNAs, nine TFs, and thirty target mRNAs were identified in relation to fibrotic processes. Thus, circulating exosomal miR-16-5p and let-7e-5p are associated with bladder fibrosis of DCP, and the crucial genes in regulatory network might hold immense significance in studying the pathogenesis and molecular mechanisms of fibrosis, which deserves further exploration.
Introduction: The Pathological Landscape of Diabetic Cystopathy
Diabetic cystopathy (DCP) is a common but often overlooked complication of chronic diabetes, characterized by bladder dysfunction, decreased sensitivity, and detrusor underactivity. A hallmark of advanced DCP is interstitial fibrosis—the excessive accumulation of collagen that stiffens the bladder wall and impairs its contractile function. Detecting these changes early remains a significant clinical challenge, as the molecular mechanisms driving the transformation of bladder fibroblasts into scar-forming myofibroblasts are not fully understood.
Methodology: Integrating Experimental and Bioinformatic Workflows
To identify non-invasive biomarkers and clarify fibrotic signaling pathways, researchers employed a multi-stage approach. Type 1 diabetes was induced in Sprague-Dawley rats using streptozotocin (STZ), and bladder fibrosis was confirmed histologically after 16 weeks.
The study focused on exosomes—extracellular vesicles used for cell-to-cell communication. Exosomes were isolated from both primary bladder fibroblasts and rat plasma. The team performed miRNA sequencing on fibroblast-derived exosomes and conducted a joint analysis with human plasma data from the GEO database (GSE97123) to identify conserved, differentially expressed miRNAs (DEMis).
Key Results: Conserved Biomarkers and Regulatory Networks
The analysis identified two specific microRNAs, miR-16-5p and let-7e-5p, which were significantly downregulated in both diabetic rats and human patients. This cross-species conservation suggests a fundamental role for these miRNAs in preventing bladder fibrosis. Quantitative PCR (qPCR) validated their decreased presence in plasma exosomes.
A miRNA-mediated genetic regulatory network was constructed, identifying a "triplex" of 2 miRNAs, 9 transcription factors (including SP1 and EGR1), and 30 hub genes. These hub genes, such as IGF1 and CCND1, are central to the PI3K-Akt, Wnt, and Hippo signaling pathways, which are known drivers of tissue remodeling and cell proliferation.
Discussion and Future Directions
The downregulation of miR-16-5p and let-7e-5p appears to release the inhibition on pro-fibrotic genes, promoting the accumulation of extracellular matrix (ECM). While plasma exosomes provide a viable diagnostic window, future studies might investigate urinary exosomes for even greater tissue specificity. Additionally, functional validation through gene knockdown or overexpression experiments is necessary to confirm the specific interactions within the predicted regulatory network. These findings provide a promising foundation for developing non-invasive diagnostics and targeted therapies for diabetic cystopathy.
Summary updated